Moreover, we identified a MYC-degrading molecule, A80.2HCl, that efficiently reduces MYC protein levels and overcomes CDK4/6i resistance (Fig. 7), shedding light on strategies for the expanded use of CDK4/6i in cancer treatment. The gene discussed is CDK4; the disease is cancer.